[go: up one dir, main page]

EA200801259A1 - Способ получения препарата инсулина для перорального применения - Google Patents

Способ получения препарата инсулина для перорального применения

Info

Publication number
EA200801259A1
EA200801259A1 EA200801259A EA200801259A EA200801259A1 EA 200801259 A1 EA200801259 A1 EA 200801259A1 EA 200801259 A EA200801259 A EA 200801259A EA 200801259 A EA200801259 A EA 200801259A EA 200801259 A1 EA200801259 A1 EA 200801259A1
Authority
EA
Eurasian Patent Office
Prior art keywords
insulin
oral
implementation
insulin preparation
method allows
Prior art date
Application number
EA200801259A
Other languages
English (en)
Other versions
EA012884B1 (ru
Inventor
Андрей Владимирович Артамонов
Петр Иванович Родионов
Original Assignee
Общество С Ограниченной Ответственностью "Концерн О3"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Концерн О3" filed Critical Общество С Ограниченной Ответственностью "Концерн О3"
Publication of EA200801259A1 publication Critical patent/EA200801259A1/ru
Publication of EA012884B1 publication Critical patent/EA012884B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение относится к фармакологии и медицине, в частности к эндокринологии. Суть способа заключается в том, что в 1-50% водный раствор водорастворимого полимера с мол. массой 0,4-40 кДа, предварительно облученного ионизирующим излучением в дозе 1,0-5,0 Мрад, вводят инсулин до конечной концентрации 1-10 мг/мл в соотношении полиэтиленоксид:инсулин, равном (1-500):1, и смесь перемешивают до получения однородного прозрачного или слегка опалесцирующего раствора. Данный способ позволяет получить фармацевтическую композицию, включающую биологически активный инсулин, обладающую высокой гипогликемической активностью при энтеральном применении. Способ позволяет упростить процесс получения энтерального препарата инсулина и повысить его терапевтическую активность.
EA200801259A 2006-09-13 2007-09-11 Способ получения препарата инсулина для перорального применения EA012884B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2006132763/15A RU2316339C1 (ru) 2006-09-13 2006-09-13 Способ получения препарата инсулина для перорального применения
PCT/RU2007/000483 WO2008033058A2 (en) 2006-09-13 2007-09-11 Method for producing insulin in the form of an oral preparation

Publications (2)

Publication Number Publication Date
EA200801259A1 true EA200801259A1 (ru) 2008-08-29
EA012884B1 EA012884B1 (ru) 2009-12-30

Family

ID=39184228

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801259A EA012884B1 (ru) 2006-09-13 2007-09-11 Способ получения препарата инсулина для перорального применения

Country Status (13)

Country Link
US (1) US20090312235A1 (ru)
EP (1) EP2067484A4 (ru)
JP (1) JP2010503665A (ru)
CN (1) CN101384276A (ru)
AU (1) AU2007295132A1 (ru)
CA (1) CA2662799A1 (ru)
EA (1) EA012884B1 (ru)
IL (1) IL197470A0 (ru)
MX (1) MX2009001286A (ru)
RU (1) RU2316339C1 (ru)
UA (1) UA93254C2 (ru)
WO (1) WO2008033058A2 (ru)
ZA (1) ZA200807272B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA90013C2 (ru) 2008-03-19 2010-03-25 Давид Анатолійович Нога Фармацевтическая композиция, содержащая инсулин, и способ его получения
RU2395296C1 (ru) * 2009-02-19 2010-07-27 Общество С Ограниченной Ответственностью "Концерн О3" Способ получения препарата проинсулина для перорального применения
RU2413531C2 (ru) * 2009-03-31 2011-03-10 Общество С Ограниченной Ответственностью "Концерн О3" Способ получения препарата с-пептида проинсулина для перорального применения
RU2441036C1 (ru) * 2010-09-30 2012-01-27 Общество с ограниченной ответственностью Научно-производственное объединение "Перспектива" (ООО НПО "Перспектива") Способ получения активированного полиэтиленоксида
RU2452509C1 (ru) * 2011-01-31 2012-06-10 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" ООО "Саентифик Фьючер Менеджмент" Средство для стимуляции роста организма
SG11201403207WA (en) * 2011-12-12 2014-09-26 Melior Pharmaceuticals I Inc Treatment of type i and type ii diabetes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2066551C1 (ru) * 1994-03-23 1996-09-20 Институт нефтехимического синтеза РАН Способ получения инсулинсодержащих полимерных гидрогелей
RU2117488C1 (ru) * 1997-07-30 1998-08-20 Институт нефтехимического синтеза им.А.В.Топчиева РАН Твердое инсулинсодержащее лекарственное средство
RU2213557C2 (ru) * 2001-12-26 2003-10-10 Закрытое акционерное общество "Аксис" Фармацевтическая композиция, обладающая тромболитическими, противовоспалительными и цитопротективными свойствами

Also Published As

Publication number Publication date
CN101384276A (zh) 2009-03-11
EA012884B1 (ru) 2009-12-30
UA93254C2 (ru) 2011-01-25
EP2067484A4 (de) 2009-10-28
EP2067484A2 (de) 2009-06-10
US20090312235A1 (en) 2009-12-17
CA2662799A1 (en) 2008-03-20
RU2316339C1 (ru) 2008-02-10
ZA200807272B (en) 2009-07-29
JP2010503665A (ja) 2010-02-04
AU2007295132A1 (en) 2008-03-20
MX2009001286A (es) 2009-03-20
WO2008033058A3 (en) 2008-05-08
IL197470A0 (en) 2011-08-01
WO2008033058A2 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
CA2843504C (en) Protein carrier-linked prodrugs
US9062094B2 (en) Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
US9533056B2 (en) Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
AU2012296950B2 (en) Polymeric hyperbranched carrier-linked prodrugs
EA200700389A1 (ru) Стабильный при хранении инфузионный раствор дигидроптеридинонов
UA95488C2 (ru) Концентрированный раствор метотрексата для подкожного введения
ATE424848T1 (de) Pharmazeutische zusammensetzungen für die kontrollierte freigabe von biologischen wirkstoffen
MY152304A (en) An insulin conjugate using an immunoglobulin fragment
US20140296257A1 (en) High-Loading Water-Soluable Carrier-Linked Prodrugs
EA200801259A1 (ru) Способ получения препарата инсулина для перорального применения
WO2018226160A1 (en) Microneedle patch loaded with a fat browning agent and a method for preparing the same
AR074357A1 (es) Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas. metodo de dialisis in vitro
KR20200009611A (ko) 염증 억제 펩타이드의 물리적/화학적 함유 주사 제형 전달체, 이의 제조 방법 및 응용
UA116569C2 (uk) Фармацевтична композиція для пролонгованого вивільнення ланреотиду
DE60111637D1 (de) Biomaterial in form von mikropartikeln von hyaluronsaure zur medizinischen verwendung
CN105935353A (zh) 一种胸腺法新缓释微球制剂及其制备方法
EP3442557B1 (en) A drug formulation for use in the effective control of acute and/or chronic pain
CN114096269B (zh) 高浓度胰岛素制剂
RU2560678C2 (ru) Способ повышения неспецифической резистентности организма в условиях холодового воздействия
MX2024002920A (es) Formulaciones farmaceuticas inyectables de alta concentracion y metodos de preparacion y uso de las mismas.
WO2025171300A1 (en) Lipids and lipid nanoparticles comprising the same
HK1198630B (en) Protein carrier-linked prodrugs

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KZ RU